Enough people have been infected that the virus can no longer spread easily
In the long, cyclical struggle between human populations and the dengue virus, Singapore has arrived at a rare moment of reprieve — recording just 3,990 cases in 2025, a 70 percent decline from the year before and the lowest count in seven years. Four lives were lost, compared to seventeen in 2024, a quieter toll that reflects both deliberate intervention and the ancient mathematics of immunity. Scientists credit a combination of forces: a pioneering program releasing Wolbachia-carrying mosquitoes to suppress transmission, and the likelihood that enough people have now encountered the dominant strain to slow its passage through the population. Yet those who study the disease most closely know that dengue does not surrender — it waits.
- After years of surging infections, Singapore's dengue burden collapsed by 70% in 2025, with deaths falling from 17 to just 4 — a shift so dramatic it demands explanation.
- Project Wolbachia, now reaching over 580,000 households with lab-bred mosquitoes designed to suppress Aedes populations, has been substantially scaled up and is widely credited as a contributing force.
- Infectious disease experts argue the more immediate driver may be herd immunity — enough Singaporeans have encountered the dominant Den-2 strain that the virus is running out of susceptible hosts, mirroring an almost identical collapse seen in 2017.
- The global picture echoes Singapore's: worldwide dengue cases fell from roughly 14 million to five million, with Malaysia, Brazil, and other hard-hit nations all reporting steep declines in 2025.
- Beneath the relief, a warning is already materializing — Den-3 cases are climbing in Singapore, and history shows that when a new or long-absent serotype rises, populations with no prior immunity become vulnerable almost overnight.
Singapore's dengue crisis has quietly retreated. By late December 2025, the city-state had recorded just 3,990 infections — a 70 percent collapse from the previous year's 13,651 cases — and only four deaths, down from seventeen in 2024. It is the lowest case count since 2018.
The causes remain intertwined. Public health officials point to Project Wolbachia, which releases laboratory-bred male mosquitoes carrying a bacterium that suppresses the Aedes population responsible for transmission. The program now covers more than 580,000 households and is set to reach 800,000 by 2026. Professor Hsu Li Yang of the National University of Singapore called its contribution "very likely" significant, while cautioning that dengue numbers have swung so wildly in recent years that isolating the program's precise effect will take another two to three years to determine.
Infectious diseases expert Paul Tambyah offers a complementary explanation: herd immunity. He argues that the most probable driver is simply that enough Singaporeans have now been infected with the currently circulating Den-2 serotype that the virus can no longer spread easily. The pattern mirrors 2017, when Singapore saw a nearly identical 79 percent drop — also during a period of Den-2 dominance — suggesting a cyclical rhythm in which immunity accumulates until the disease exhausts its pool of susceptible hosts.
The retreat is global. Worldwide dengue cases fell from roughly 14 million in 2024 to approximately five million by late 2025, with deaths dropping from around 9,500 to about 3,000. Malaysia reported a 56 percent decline; Brazil saw cases fall from 6.4 million to 1.6 million, aided by mosquito control and national vaccination efforts. Tambyah noted that increased international travel since the pandemic has likely synchronized dengue trends across countries.
The respite, however, may be temporary. Den-3 cases are already rising in Singapore, and the city-state's 2020 surge — driven by Den-3 and Den-4 strains that had not circulated widely for years — is a reminder of how quickly vulnerability can return. Immunity to one of dengue's four serotypes offers no protection against the others. For now, Singapore can breathe easier. But the virus is still circulating, still waiting.
Singapore's dengue crisis has quietly retreated. As of late December 2025, the city-state had recorded just 3,990 cases of the mosquito-borne illness—a stunning 70 percent collapse from the previous year's 13,651 infections. The death toll fell even more sharply, from 17 fatalities in 2024 to four this year. It is the lowest case count Singapore has seen since 2018, when 3,282 infections were documented.
The decline is real, but its causes remain tangled. Public health officials point to Project Wolbachia, an initiative that releases laboratory-bred male mosquitoes carrying the Wolbachia bacterium into the environment to suppress the Aedes mosquito population that transmits dengue. The program now reaches more than 580,000 households and is slated to expand to 800,000—roughly half of all Singapore households—by 2026. Professor Hsu Li Yang, vice-dean of global health at the National University of Singapore's Saw Swee Hock School of Public Health, said the project has "very likely" contributed to the decline and has been substantially scaled up over the past year. Yet he cautioned that dengue case numbers have swung wildly in recent years, making it difficult to isolate Wolbachia's precise impact. The true measure of the program's effectiveness, he suggested, will emerge over the next two to three years.
Another explanation may be simpler: herd immunity. Paul Tambyah, an infectious diseases expert and immediate past president of the International Society for Infectious Diseases, argues that the most probable driver of the dramatic drop is that enough people in Singapore have now been infected with the currently circulating strains of dengue that the virus can no longer spread as easily. He drew a striking parallel to 2017, when Singapore experienced an almost identical 78.9 percent decline in cases—from 13,085 in 2016 to 2,767 in 2017. Both periods were dominated by the Den-2 serotype of dengue, suggesting a cyclical pattern in which immunity builds until the disease runs out of susceptible hosts.
Singapore's recovery is part of a broader global retreat from dengue. Worldwide, approximately five million cases were recorded by early December 2025, down sharply from about 14 million in 2024. Deaths fell from roughly 9,500 to about 3,000. The decline spans the region: Malaysia reported a 56 percent drop to 51,046 cases in 2025, down from 118,291 the year before. Brazil, which had been devastated by dengue, saw cases plummet from 6.4 million in 2024 to 1.6 million in 2025, a reduction attributed to mosquito control efforts and national vaccination campaigns. Tambyah noted that increased international travel since the Covid-19 pandemic has likely synchronized dengue trends across countries, meaning what happens in one region often echoes in others.
But the respite may be temporary. Tambyah warned that the downward trend could reverse if a new dengue serotype gains dominance. In 2020, Singapore experienced a surge driven by Den-3 and Den-4 strains, neither of which had infected large numbers of people previously, leaving the population vulnerable. While Den-2 remains the predominant serotype in Singapore today, the number of Den-3 cases is already climbing, according to data from the National Environment Agency. The disease has a way of returning when people least expect it, and dengue's four distinct serotypes mean that immunity to one strain offers no protection against the others. For now, Singapore can breathe easier. But the virus is still circulating, still mutating, still waiting.
Notable Quotes
Project Wolbachia has 'very likely' contributed to the decline in dengue numbers in 2025, though it is difficult to judge how much of a role the project has played given how wildly case numbers have fluctuated in recent years.— Professor Hsu Li Yang, vice-dean of global health at NUS Saw Swee Hock School of Public Health
The most likely reason for the dramatic drop is growing herd immunity—when enough people are immune to a disease such that it no longer spreads easily—to currently circulating strains of dengue.— Paul Tambyah, infectious diseases expert and immediate past president of the International Society for Infectious Diseases
The Hearth Conversation Another angle on the story
Why did dengue cases drop so dramatically this year? Was it one thing or many?
It's genuinely unclear. Project Wolbachia—releasing infected male mosquitoes to suppress the Aedes population—has likely helped, and it's been scaled up significantly. But the expert consensus leans toward herd immunity as the main driver. Enough people have been infected with the Den-2 strain that it simply can't spread as easily anymore.
So this happened before?
Yes, in 2017. Almost the same pattern—a 78.9 percent drop in cases. Den-2 was dominant then too. It suggests dengue follows cycles, not a straight line.
What's the global picture?
Dengue cases worldwide fell from 14 million to 5 million. Brazil, Malaysia, Singapore—all seeing sharp declines. But that's partly because travel patterns have synchronized the disease across regions.
Is this permanent?
Almost certainly not. Experts are already watching Den-3 cases creep upward. If a new serotype becomes dominant, the whole cycle could reverse. Dengue has four strains, and immunity to one doesn't protect you from the others.
So the city-state got lucky?
Not entirely luck. The Wolbachia program is real, the vaccination efforts in other countries are real. But timing and immunity matter more than we can measure right now. The next two or three years will tell us whether Wolbachia is truly the game-changer.